| Company name | Bactheravax |
| Year of establishment | 2026 |
| Sector | Life Sciences & Health |
| Website | https://bactheravax.com/ |
| Status | Active |
Bactheravax
Bactheravax is developing a therapeutic vaccine against Fusobacterium nucleatum, a tumour-associated bacterium implicated in colorectal-cancer progression and treatment resistance. The preclinical company aims to improve the effectiveness of established cancer therapies by selectively modulating the tumour microenvironment
This investment is managed by
, at UNIIQ.
